XML 40 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 6 - Stockholders' Equity (Details Textual)
3 Months Ended 9 Months Ended
Jun. 17, 2017
Jan. 01, 2017
shares
Feb. 12, 2016
USD ($)
$ / shares
shares
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
shares
Dec. 31, 2016
USD ($)
shares
Dec. 31, 2015
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number       2,613,299   2,613,299   2,484,445  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $       $ 181,537   $ 181,537   $ 171,537  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           150,000      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.25      
Class of Warrant or Right, Outstanding       3,826,658   3,826,658     3,826,658
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price | $ / shares       $ 1.05   $ 1.05     $ 1.02
Class of Warrant or Right Outstanding, Aggregate Intrinsic Value | $       $ 763,342   $ 763,342      
Fair Value Adjustment of Warrants | $           $ 99,782    
Warrants with Extended Term [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       100,000   100,000      
Private Placement [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     423,291            
Private Placement [Member] | General and Administrative Expense [Member]                  
Fair Value Adjustment of Warrants | $           $ 99,782      
Protagenic Therapeutics Inc [Member]                  
Business Combination, Stock Warrant Conversion Ratio     1            
Debt Instrument, Face Amount | $     $ 665,000            
Debt Instrument, Increase, Accrued Interest | $     $ 35,000            
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     295,945            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.25            
Class of Warrant or Right, Expiration Period     5 years            
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     127,346            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.25            
Protagenic Therapeutics Inc [Member] | Private Placement [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     3,403,367            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.05            
Employee Stock Option [Member]                  
Allocated Share-based Compensation Expense | $       $ 153,830 $ 273,674 654,707 $ 450,566    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $       $ 880,075   $ 880,075      
The 2016 Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized   564,378              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant   2,712,678              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           150,000 1,201,084    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.25      
The 2006 Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           0 100,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.25